10-Q: Raphael Pharmaceutical Inc. Reports Increased Net Loss in Second Quarter 2024 Amidst Ongoing Clinical Trials

Raphael Pharmaceutical Inc. reported a net loss of $798,000 for the six months ended June 30, 2024, as the company continues to invest in research and development.

Summary

• Raphael Pharmaceutical Inc. reported a net loss of $798,000 for the six months ended June 30, 2024, compared to a net loss of $681,000 for the same period in 2023.
• The company's operating loss increased to $796,000 for the six months ended June 30, 2024, up from $677,000 in the prior year.
• Research and development expenses were $403,000 for the six months ended June 30, 2024, a slight decrease from $407,000 in the same period of 2023.
• General and administrative expenses increased to $393,000 for the six months ended June 30, 2024, compared to $270,000 in the prior year.
• The company had $120,000 in cash and cash equivalents as of June 30, 2024, down from $230,000 at the end of 2023.
• The company is in the pre-clinical development stage for its lead product candidate for rheumatoid arthritis (RA) and is also developing a treatment for hyperinflammatory syndrome and lung inflammation related to COVID-19.
• A proof-of-concept clinical trial for the RA product candidate commenced in the USA in April 2024, with an estimated timeline of six months to finalize after the first participant is recruited.
• The company has an accumulated deficit of $8,108,000 as of June 30, 2024, and has not yet generated any revenue.
• The company anticipates needing approximately $700,000 for research and development and $500,000 for capital expenditures over the next 12 months.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a decreasing cash position, and substantial doubt about the company's ability to continue as a going concern. While there are some positive developments in clinical trials, the overall financial outlook is concerning.

Positives

• The company commenced a proof-of-concept clinical trial in the USA for its RA product candidate in April 2024.
• The company has completed pre-clinical studies on human-derived immune cells and mouse models for both the COVID-19 and RA products.
• The company has engaged with Citruslabs to oversee the proof-of-concept clinical trial, ensuring adherence to industry standards.
• The company has a research agreement with Rambam MT for the development of a new, patentable formulation to treat rheumatoid diseases.

Negatives

• The company's net loss increased by 17.2% to $798,000 for the six months ended June 30, 2024, compared to $681,000 for the same period in 2023.
• The company's cash and cash equivalents decreased to $120,000 as of June 30, 2024, from $230,000 at the end of 2023.
• The company has an accumulated deficit of $8,108,000 as of June 30, 2024.
• The company has not generated any revenue to date and does not expect to generate significant revenue in the near future.
• The company's current cash on hand is not sufficient to fund projected operating requirements, raising substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient cash and the need for additional financing.
• There is no guarantee that the company will be able to obtain additional financing on acceptable terms or at all.
• The company is still in the development and clinical stage and has not yet generated revenues.
• The company's future success depends on the successful completion of clinical trials and obtaining regulatory approvals.
• The company faces risks related to the commercial launch and future sales of its product candidates.
• The company is subject to risks related to third-party payor reimbursement for its product candidates.
• The company's operating plans may change due to various factors, and it may need to seek additional funds sooner than planned.

Future Outlook

The company anticipates needing approximately $700,000 for research and development activities and $500,000 for capital expenditures over the next 12 months and will require significant additional financing in the near future to fund its operations. The company expects to continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity.

Management Comments

• Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity.
• Management has concluded that substantial doubt about the Company's ability to continue as a going concern exists in the event that additional funding does not occur.
• Management plans include raising capital in the United States.

Industry Context

The company is operating in the pharmaceutical drug research and development sector, specifically focusing on cannabinoid-based therapies. This is a growing area of interest, with increasing research into the potential therapeutic benefits of cannabinoids. The company's focus on rheumatoid arthritis and COVID-19 related inflammation aligns with current medical needs and research trends.

Comparison to Industry Standards

• Raphael Pharmaceutical is a development stage company with no revenue, which is typical for early-stage biotech firms.
• The company's cash burn rate is significant, with a net loss of $798,000 for the first six months of 2024, which is not unusual for companies in the clinical trial phase.
• The company's reliance on equity financing is common for biotech startups, but the need for additional funding raises concerns about dilution for existing shareholders.
• Compared to established pharmaceutical companies, Raphael is in a much earlier stage of development and faces significant risks related to clinical trial success and regulatory approvals.
• The company's research agreement with Rambam Hospital is similar to collaborations seen in the industry, where companies partner with research institutions to advance their drug development programs.
• The company's focus on cannabinoid-based therapies is a growing trend in the pharmaceutical industry, with several other companies exploring similar approaches.

Stakeholder Impact

• Shareholders face the risk of further dilution due to the need for additional financing.
• Employees may be impacted by the company's financial instability and potential restructuring.
• Customers and patients may be impacted by delays in the development and commercialization of the company's product candidates.
• Suppliers and creditors may be impacted by the company's financial instability and potential inability to meet its obligations.

Next Steps

• The company will continue its proof-of-concept clinical trial for the RA product candidate in the USA.
• The company will continue to investigate and refine the formula through continued pre-clinical research.
• The company will seek additional financing to fund its operations.
• The company will work towards obtaining regulatory approvals for its product candidates from the FDA and the Medical Cannabis Unit of the Israeli Ministry of Health.

Key Dates

Keywords

pharmaceutical, cannabinoids, CBD, rheumatoid arthritis, COVID-19, clinical trials, research and development, financial results, net loss, going concern